Annual CFO
-$118.11 M
-$311.72 M-161.00%
31 December 2023
Summary:
Foghorn Therapeutics annual cash flow from operations is currently -$118.11 million, with the most recent change of -$311.72 million (-161.00%) on 31 December 2023. During the last 3 years, it has fallen by -$86.82 million (-277.50%). FHTX annual CFO is now -161.00% below its all-time high of $193.61 million, reached on 31 December 2022.FHTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$21.00 M
+$4.53 M+17.75%
30 September 2024
Summary:
Foghorn Therapeutics quarterly cash flow from operations is currently -$21.00 million, with the most recent change of +$4.53 million (+17.75%) on 30 September 2024. Over the past year, it has increased by +$6.21 million (+22.80%). FHTX quarterly CFO is now -107.74% below its all-time high of $271.53 million, reached on 31 March 2022.FHTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$103.43 M
+$6.21 M+5.66%
30 September 2024
Summary:
Foghorn Therapeutics TTM cash flow from operations is currently -$103.43 million, with the most recent change of +$6.21 million (+5.66%) on 30 September 2024. Over the past year, it has increased by +$16.06 million (+13.44%). FHTX TTM CFO is now -142.31% below its all-time high of $244.43 million, reached on 31 March 2022.FHTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
FHTX Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -161.0% | +22.8% | +13.4% |
| 3 y3 years | -277.5% | -2.5% | -42.1% |
| 5 y5 years | -421.5% | - | - |
FHTX Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -161.0% | at low | -107.7% | +34.7% | -142.3% | +13.4% |
| 5 y | 5 years | -161.0% | at low | -107.7% | +34.7% | -142.3% | +13.4% |
| alltime | all time | -161.0% | at low | -107.7% | +34.7% | -142.3% | +13.4% |
Foghorn Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$21.00 M(-17.7%) | -$103.43 M(-5.7%) |
| June 2024 | - | -$25.54 M(-13.0%) | -$109.63 M(-5.7%) |
| Mar 2024 | - | -$29.34 M(+6.6%) | -$116.27 M(-1.6%) |
| Dec 2023 | -$118.11 M(-161.0%) | -$27.54 M(+1.2%) | -$118.11 M(-1.2%) |
| Sept 2023 | - | -$27.21 M(-15.4%) | -$119.49 M(+6.4%) |
| June 2023 | - | -$32.17 M(+3.2%) | -$112.27 M(+2.9%) |
| Mar 2023 | - | -$31.18 M(+7.8%) | -$109.10 M(-156.4%) |
| Dec 2022 | $193.61 M | -$28.92 M(+44.7%) | $193.61 M(-17.4%) |
| Sept 2022 | - | -$19.99 M(-31.1%) | $234.42 M(+0.2%) |
| June 2022 | - | -$29.01 M(-110.7%) | $233.90 M(-4.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $271.53 M(+2185.3%) | $244.43 M(-586.4%) |
| Dec 2021 | -$50.25 M(+60.6%) | $11.88 M(-158.0%) | -$50.25 M(-31.0%) |
| Sept 2021 | - | -$20.50 M(+10.9%) | -$72.79 M(+46.9%) |
| June 2021 | - | -$18.48 M(-20.1%) | -$49.56 M(+13.5%) |
| Mar 2021 | - | -$23.15 M(+117.2%) | -$43.67 M(+39.6%) |
| Dec 2020 | -$31.29 M(-32.5%) | -$10.65 M(-490.9%) | -$31.29 M(+51.6%) |
| Sept 2020 | - | $2.73 M(-121.6%) | -$20.63 M(-11.7%) |
| June 2020 | - | -$12.60 M(+17.0%) | -$23.36 M(+117.0%) |
| Mar 2020 | - | -$10.76 M | -$10.76 M |
| Dec 2019 | -$46.34 M(+104.6%) | - | - |
| Dec 2018 | -$22.65 M | - | - |
FAQ
- What is Foghorn Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Foghorn Therapeutics?
- What is Foghorn Therapeutics annual CFO year-on-year change?
- What is Foghorn Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Foghorn Therapeutics?
- What is Foghorn Therapeutics quarterly CFO year-on-year change?
- What is Foghorn Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Foghorn Therapeutics?
- What is Foghorn Therapeutics TTM CFO year-on-year change?
What is Foghorn Therapeutics annual cash flow from operations?
The current annual CFO of FHTX is -$118.11 M
What is the all time high annual CFO for Foghorn Therapeutics?
Foghorn Therapeutics all-time high annual cash flow from operations is $193.61 M
What is Foghorn Therapeutics annual CFO year-on-year change?
Over the past year, FHTX annual cash flow from operations has changed by -$311.72 M (-161.00%)
What is Foghorn Therapeutics quarterly cash flow from operations?
The current quarterly CFO of FHTX is -$21.00 M
What is the all time high quarterly CFO for Foghorn Therapeutics?
Foghorn Therapeutics all-time high quarterly cash flow from operations is $271.53 M
What is Foghorn Therapeutics quarterly CFO year-on-year change?
Over the past year, FHTX quarterly cash flow from operations has changed by +$6.21 M (+22.80%)
What is Foghorn Therapeutics TTM cash flow from operations?
The current TTM CFO of FHTX is -$103.43 M
What is the all time high TTM CFO for Foghorn Therapeutics?
Foghorn Therapeutics all-time high TTM cash flow from operations is $244.43 M
What is Foghorn Therapeutics TTM CFO year-on-year change?
Over the past year, FHTX TTM cash flow from operations has changed by +$16.06 M (+13.44%)